Breast Cancer Prevention

  • Jennifer G. Reeder
  • Victor G. Vogel
Part of the Cancer Treatment and Research book series (CTAR, volume 141)

Breast cancer is a devastating illness that affects tens of thousands of American women each year. Although it is impossible to predict who will develop breast cancer, clinicians can identify women who are at increased risk for breast cancer and provide them with options to reduce their risk. A number of validated, quantitative risk-assessment models incorporate features of a patient’s medical and family history to help women more accurately estimate their individual risk and thus aid them in decision-making. Over the years, research has focused on the development of both surgical and medical methods for breast cancer risk reduction in high-risk women. This chapter will emphasize the importance of identifying and educating women at increased risk for breast cancer, and then providing them with a comprehensive breast cancer risk management plan. We will also discuss the surgical and medical options available and offer a management summary for breast cancer risk reduction.


Breast Cancer Breast Cancer Risk Prophylactic Mastectomy Breast Cancer Prevention Breast Cancer Risk Reduction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Black, W. C., Nease Jr, R. F., Tosteson, A. N. A. 1995. Perceptions of breast cancer risk and screening effectiveness in women younger than 50 years of age. J Natl Cancer Inst 87:720–31.PubMedCrossRefGoogle Scholar
  2. 2.
    Colditz, G. A., Rosner, B. 2000. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses’ Health Study. Am J Epidemiol 152:950–64.PubMedCrossRefGoogle Scholar
  3. 3.
    Vogel, V. G. 1998. Breast cancer risk factors and preventive approaches to breast cancer. In: Kavanagh J, Singletary SE, Einhorn N, et al., editors. Cancer in women. Cambridge (MA): Blackwell Scientific Publications, Inc., 58–91.Google Scholar
  4. 4.
    Vogel, VG, Bevers, T. Handbook of Breast Cancer Risk-Assessment. Evidence-Based Guidelines for Evaluation, Prevention, Counseling, and Treatment. Sudbury (MA): Jones and Bartlett Publishers; 2003.Google Scholar
  5. 5.
    Offit, K., Brown, K. 1994. Quantitation of familial cancer risk: a resource for clinical oncologists. J Clin Oncol 12:1724–36.PubMedGoogle Scholar
  6. 6.
    Wooster, R., Neuhausen, S. L., Mangion, J., et al. 1994. Localization of a breast cancer susceptibility gene, BRCA2, to chromosomes 13q12–13. Science 265:2088–90.PubMedCrossRefGoogle Scholar
  7. 7.
    Easton, D. F., Bishop, D. T., Ford, D., et al. 1993. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Am J Hum Genet 52:678–701.PubMedGoogle Scholar
  8. 8.
    Struewing, J. P., Hartge, P., Wacholder, S., et al. 1997. The risk of cancer associated with specific mutation of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401–1408.PubMedCrossRefGoogle Scholar
  9. 9.
    Dupont, W. D., Page, D. L., Parl, F. F., et al. 1994. Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med 331:10–15.PubMedCrossRefGoogle Scholar
  10. 10.
    London, S. J., Connolly, J. L., Schnitt, S. J., et al. 1992. A prospective study of benign breast disease and the risk of breast cancer. JAMA 267:941–4.PubMedCrossRefGoogle Scholar
  11. 11.
    Dupont, W. D., Page, D. L. 1985. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312:146–51.PubMedGoogle Scholar
  12. 12.
    Dupont, W. D., Parl, F. F., Hartman, W. H., et al. 1993. Breast cancer risk associated with proliferative disease and atypical hyperplasia. Cancer 71:1258–65.PubMedCrossRefGoogle Scholar
  13. 13.
    Page, D. L., Dupont, W. D., Rogers, L. W., et al. 1985. 1998. Atypical hyperplastic lesions of the female breast: a long-term follow-up study. Cancer 55:2698–708.PubMedCrossRefGoogle Scholar
  14. 14.
    Fisher, B., Costantino, J. P., Wickerham, D. L., et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–88.Google Scholar
  15. 15.
    Gail, M. H., et al. 1989. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879–86.PubMedCrossRefGoogle Scholar
  16. 16.
    Lehman, C. D., Gatsonis, C., Kuhl, C. K., et al. 2007. MRI Evaluation in the Contralateral Breast in Women with Recently Diagnosed Breast Cancer. N Engl J Med 356:1295–1303.PubMedCrossRefGoogle Scholar
  17. 17.
    Hartmann, L. C., Schaid, D. J., Woods, J. E., et al. 1999. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340:77–84.PubMedCrossRefGoogle Scholar
  18. 18.
    Meijers-Heijboer, M., van Geel, B., van Putten, W. L. J., et al. 2001. Breast cancer after prophylactic bilateral mastectomy in women with BRCA1 or BRCA2 mutation. N Engl J Med 345:154–64.CrossRefGoogle Scholar
  19. 19.
    Kauff, N. D., Satagopan, J. M., Robson, M. E., et al. 2002. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609–15.PubMedCrossRefGoogle Scholar
  20. 20.
    Rebbeck, T. R., Lynch, H. T., Neuhausen, S. L., et al. 2002. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616–22.PubMedCrossRefGoogle Scholar
  21. 21.
    Cuzick, J., Powles, T., Veronesi, U., et al. 2003. Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296–300.PubMedCrossRefGoogle Scholar
  22. 22.
    Osborne, C. K. 1989. Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609–18.CrossRefGoogle Scholar
  23. 23.
    Powles, T. J., Jones, A. L., Ashley, S. E., et al. 1994. The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat 31:73–82.PubMedCrossRefGoogle Scholar
  24. 24.
    Powles, T. J., Ashley, S., Tidy, A., et al. 2007. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99:283–90.PubMedCrossRefGoogle Scholar
  25. 25.
    Veronesi, U., Maisonneuve, P., Sacchini, V., et al. 2002. Tamoxifen for breast cancer among hysterectomised women. Lancet 359:1122–24.PubMedCrossRefGoogle Scholar
  26. 26.
    Veronesi, U., Maisonneuve, P., Rotmensz, N., et al. 2003. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 95:160–5.PubMedGoogle Scholar
  27. 27.
    IBIS Investigators. 2002. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360:817–24.CrossRefGoogle Scholar
  28. 28.
    Tyrer, J., Duffy, S. W., Cuzick, J. 2004. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23:1111–30.PubMedCrossRefGoogle Scholar
  29. 29.
    Cuzick, J., Forbes, J. F., Sestak, I., et al. for the International Breast Cancer Intervention Study (IBIS) I Investigators. 2007. Long-term results of tamoxifen prophylaxis for breast cancer-96 month follow-up of the randomized IBIS-I study. J Natl Cancer Inst 99:272–82.PubMedCrossRefGoogle Scholar
  30. 30.
    Sato, M., Glasebrook, A. L., Bryant, H. U. 1994. Raloxifene: a selective estrogen receptor modulator. J Bone Miner Metab 12:S9–S20.CrossRefGoogle Scholar
  31. 31.
    Bryant, H. U., Glasebrook, A. L., Yang, N. N., et al. 1996. A pharmacological review of raloxifene. J Bone Miner Metab 14:1–9.CrossRefGoogle Scholar
  32. 32.
    Delmas, P. D., Bjarnason, N. H., Mitlak, B. H., et al. 1997. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641–47.PubMedCrossRefGoogle Scholar
  33. 33.
    Ettinger, B., Black, D. M., Mitlak, B. H., et al. 1999. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637–45.PubMedCrossRefGoogle Scholar
  34. 34.
    Cummings, S. R., Eckert, S., Krueger, K. A., et al. 1999. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 281:2189–97.PubMedCrossRefGoogle Scholar
  35. 35.
    Lippman, M. E., Krueger, K. A., Eckert, S., et al. 2001. Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the Multiple Outcomes of Raloxifene Evaluation study participants. J Clin Oncol 19:3111–16.PubMedGoogle Scholar
  36. 36.
    Cummings, S. R., Duong, T., Kenyon, T., et al. 2002. Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 287:216–20.PubMedCrossRefGoogle Scholar
  37. 37.
    Cauley, J. A., Norton, L., Lippman, M. E., et al. 2001. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat 65:125–34.PubMedCrossRefGoogle Scholar
  38. 38.
    Grady, D., Ettinger, B., Moscarelli, E., et al. 2004. Safety and adverse effects associated with raloxifene: Multiple Outcomes of Raloxifene Evaluation. Obstet Gynecol 104:837–44.PubMedGoogle Scholar
  39. 39.
    Martino, S., Cauley, J. A., Barrett-Connor, E., et al. 2004. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96:1751–61.PubMedGoogle Scholar
  40. 40.
    Lippman, M. E., Cummings, S. R., Disch, D. P., et al. 2006. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk. Clin Cancer Res 12:5242–47.PubMedCrossRefGoogle Scholar
  41. 41.
    Barrett-Connor, E., Grady, D., Sashegyi, A., et al. 2002. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287:847–57.PubMedCrossRefGoogle Scholar
  42. 42.
    Ensrud, K., Genazzani, A. R., Geiger, M. J., et al. 2006. Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. Am J Cardiol 97:520–27.PubMedCrossRefGoogle Scholar
  43. 43.
    Barrett-Connor, E., Mosca, L., Collins, P., et al. 2006. Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125–37.PubMedCrossRefGoogle Scholar
  44. 44.
    Vogel, V. G., Costantino, J. P., Wickerham, D. L., et al. 2006. National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2727–41.PubMedCrossRefGoogle Scholar
  45. 45.
    Day, R. 2001. Quality of life and tamoxifen in a breast cancer prevention trial: a summary of findings from the NSABP P-1 study. Ann N Y Acad Sci 949:143–150.PubMedCrossRefGoogle Scholar
  46. 46.
    Land, S. R., Wickerham, D. L., Costantino, J. P., et al. 2006. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2742–51.PubMedCrossRefGoogle Scholar
  47. 47.
    McHorney, C. A., Ware Jr, J. E., Lu, J. F., Sherbourne, C. D. 1994. The MOS 36-item Short-Form Health Survey (SF-36), III: tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 32:40–66.PubMedCrossRefGoogle Scholar
  48. 48.
    McHorney, C. A., Ware Jr, J. E., Raczek, A. E. 1993. The MOS 36-Item Short-Form Health Survey (SF-36), II: psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 31:247–63.PubMedCrossRefGoogle Scholar
  49. 49.
    Ware, J. E. Jr, Sherbourne, C. D. 1992. The MOS 36-item short-form health survey (SF-36), I: conceptual framework and item selection. Med Care 30:473–83.PubMedCrossRefGoogle Scholar
  50. 50.
    McHorney, C. A., Ware Jr, J. E., Rogers, W., et al. 1992. The validity and relative precision of MOS short- and long-form health status scales and Dartmouth COOP charts: results from the Medical Outcomes Study. Med Care 30(5 suppl):MS253–MS265.PubMedCrossRefGoogle Scholar
  51. 51.
    Radloff, L.S. 1977. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1:385–401.CrossRefGoogle Scholar
  52. 52.
    Sherbourne, C. D. 1992. Social functioning: sexual problems measures. In: Stewart AL, Ware JE, editors. Measuring functioning and well-being: The Medical Outcomes Study approach. Durham, NC: Duke University Press, 194–204.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Jennifer G. Reeder
    • 1
  • Victor G. Vogel
    • 2
  1. 1.Department of MedicineUniversity of PittsburghPittsburghUSA
  2. 2.University of Pittsburgh School of MedicineMagee-Womens HospitalPittsburghUSA

Personalised recommendations